Response to Comments: MolDX: Oncotype DX AR-V7 Nucleus Detect for Men with Metastatic Castrate Resistant Prostate Cancer (MCRPC)

This document is a Response to Comments for the MolDX Oncotype DX AR-V7 Nucleus Detect policy and only records procedural dates (comment period 06/07/2018–08/14/2018; notice period 01/15/2019–03/01/2019) and that LCD DL37744 becomes effective 03/02/2019. It does not contain clinical indications, limitations, frequency, or documentation requirements for coverage — consult LCD DL37744 for the substantive coverage criteria.

"This document is a Response to Comments only and provides procedural dates: comment period 06/07/2018–08/14/2018; notice period 01/15/2019–03/01/2019; LCD DL37744 becomes effective 03/02/2019. It d..."

Sign up to see full coverage criteria, indications, and limitations.